The greatest promise for using the tumoral EV-specific gDNAs as an early cancer diagnosis biomarker might be to specifically extract tumor EVs from the whole circulating EV population by capture on “lab-on-chip” solutions, for example, by targeting some tumor-specific EV outer membrane proteins, such as glypican-1, followed by the use of the new PCR technologies for reaching the cancer-specific mutation(s) of interest. The gene discussed is GPC1; the disease is cancer.